



# ANIRIT VENTURES LIMITED

(Formerly Known as Flora Textiles Limited)

CIN: L72100TZ1993PLC004290

Registered Office: 23, Bharathi Park Road, Coimbatore - 641043, Tamil Nadu, India.

Website: [www.floratextiles.in](http://www.floratextiles.in) Email: [aniritventures@gmail.com](mailto:aniritventures@gmail.com)

**Date: February 13<sup>th</sup>, 2025**

**To,**  
**The Listing Department,**  
**BSE Limited,**  
Floor 25, P. J. Towers,  
Dalal Street, Mumbai 400 001  
**BSE Scrip Code: 530705**

**Sub.: Newspaper Advertisement for Unaudited Financial Results of the Company for quarter and nine months ended December 31, 2024 – Disclosure under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Dear Sir/Madam,**

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the copy of newspaper advertisement for the publication of unaudited Financial Results of the Company for quarter and nine months ended December 31, 2024, published in the following newspapers:

1. Trinity Mirror
2. Makkal Kural

The said newspaper advertisement provides a Quick Response ('QR') code along with the weblink of the Company's website to access complete financial results for the quarter and nine months ended December 31, 2024.

You are requested to take the same on records pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You.

Yours faithfully,

**For Anirit Ventures Limited**  
**(Formerly known as Flora Textiles Limited)**

**Visha Jain**  
**Company Secretary & Compliance officer**  
**Membership No.: 73776**

**Enclosed: as above**

Health Matters

# Drug to counteract muscle loss & osteoporosis



Rapid weight loss affects muscle mass and can increase the risk of osteoporosis. But now there is good news for people taking weight loss medication who may be at risk. A new study from Aarhus University indicates that the drug bimagrumab can counteract the side effects.

Weight loss medication has taken the world by storm and helped many overweight people. But for some, significant weight loss also comes with a loss of muscle mass and can lead to an increased risk of osteoporosis.

New research now suggests that the drug, bimagrumab, may be able to alleviate some of this risk, says PhD student Frederik Duch Bromer and postdoc Andreas Lodberg from the Department of Biomedicine at Aarhus University, who are behind the study.

"We are the first to study how certain drugs affect bones, and the results show that bimagrumab can increase the amount of bone tissue while building muscle mass, and this could be very important for the many people currently taking weight loss medication."

Bimagrumab was originally developed to treat muscle loss and dysfunction, but since then, it has become apparent that it also has a fat "burning" component to it. So, if approved, it could be part of a second-generation weight loss drug on the market.

Therefore, it's relevant to research how this particular patient group reacts to the drug," says Andreas Lodberg. "An estimated two billion people will be categorised as overweight by 2035, so it's also important that we research the drugs that come on the market for this particular patient group in order to better understand their long-term impact on the body."

Patients on weight loss medication often have a history of weight fluctuation, which can contribute

to the development of osteoporosis. Brittle bones increase the risk of serious fractures, and this is costly for both patients and society.

Therefore, the research results could be good news for patients on weight loss medication. And according to Frederik Duch Bromer, the study shows that bimagrumab not only counteracts the breakdown of bone and muscle tissue, it actually promotes the build-up of both.

"Bimagrumab slightly increases the calcium content in bones and promotes the formation of new bone in what we call the shell (cortex) of the long bones. We also saw a significant build-up of bone tissue in the area around the femoral head, which is typically where many older people incur fractures."

## Mitochondria may hold key to curing diabetes

Mitochondria are essential for generating energy that fuels cells and helps them function.

Mitochondrial defects, however, are associated with the development of diseases such as type 2 diabetes. Patients who suffer from this disorder are unable to produce enough insulin or use the insulin produced by their pancreas to keep their blood sugar at normal levels.

Several studies have shown that insulin-producing pancreatic  $\beta$ -cells of patients with diabetes have abnormal mitochondria and are unable to generate energy. Yet, these studies were unable to explain why the cells behaved this way.

In a study published in Science, researchers at the University of Michigan used mice to show that dysfunctional mitochondria trigger a response that affects the maturation and function of  $\beta$ -cells.

"We wanted to determine which pathways are important for maintaining proper mitochondrial function," said Emily M. Walker, Ph.D., a research assistant professor of internal medicine and first author of the study. To do so, the team damaged three components that are essential for mitochondrial function: their DNA, a pathway used to get rid of damaged mitochondria, and one that maintains a healthy pool of mitochondria in the cell.

"In all three cases, the exact same stress response was turned on, which caused  $\beta$ -cells to become immature, stop making enough insulin, and essentially stop being  $\beta$ -cells," Walker said.

"Our results demonstrate that the mitochondria can send signals to the nucleus and change the fate of the cell."

The researchers also confirmed their findings in human pancreatic islet cells.

Their results prompted the team to expand their search into other cells that are affected during diabetes.

"Diabetes is a multi-system disease - you gain weight, your liver produces too much sugar and your muscles are affected.

# New Mosquito species found in Sri Lanka is a health hazard



Sri Lanka has become home to a newly discovered mosquito species, unique to the island nation, according to entomologist Gayan Sri Kumarasinghe of the Medical Research Institute (MRI). This discovery, confirmed through genetic testing in South Korean laboratories, marks a significant development in Sri Lanka's entomological landscape and raises concerns about potential public health implications.

The mosquito, which feeds on both animal and human blood, presents a particular challenge. This feeding behavior creates a pathway for potential virus transmission from animals to humans, a phenomenon known as zoonotic transmission. This raises the specter of new or re-emerging viral diseases impacting the hu-

man population. While the specific viruses this new species might transmit are yet unknown, its dual feeding habit necessitates further investigation and vigilance.

The discovery is the culmination of approximately a year of research conducted by the MRI, under the guidance of Director Dr. Suranga Dolamulla and mosquito expert Dr. Rohitha Muthugala. The confirmation of its unique genetic makeup in South Korea underscores the rigorous scientific process involved. Interestingly, this is the fourth new mosquito species identified in Sri Lanka by the MRI in the past five years, highlighting a dynamic and evolving insect ecosystem on the island. This trend suggests that ongoing surveillance and research are crucial

for understanding and managing the potential health risks associated with these changes.

While the new species remains unnamed, its official naming and unveiling are anticipated soon. This formal classification will be a critical step in facilitating further research and developing targeted control strategies. Until then, the scientific community emphasizes the importance of continued surveillance and the implementation of

robust mosquito control measures to mitigate any potential health risks. Understanding the mosquito's biology, behavior, and potential disease vector capabilities will be essential for protecting public health in Sri Lanka. The discovery serves as a reminder of the ongoing need for research and monitoring of vector-borne diseases, particularly in regions experiencing environmental and ecological changes.

## Study on challenges faced by people living with obesity

Chennai, Feb 11: A recent study conducted by Novo Nordisk, involving over 2,000 people living with obesity (PwO) and 300 healthcare professionals (HCPs), has revealed critical insights into the challenges faced by PwO in India. The study highlights a significant disconnect between awareness, understanding and management of obesity, underscoring the need for an integrated, long-term approach to treatment.

It also underlines the growing need for a comprehensive approach to obesity management in India. The study identifies that one-third of PwO in India do not recognise the severity of their condition, often believing they are merely overweight or even of normal weight. This denial of obesity reflects widespread misconceptions and a lack of awareness on its implications, which contributes to delayed treatment and worse health outcomes.

PwO face significant barriers in their weight loss journeys and im-

mense difficulties in maintaining weight loss. Over half of those surveyed report reverting to old eating habits despite their efforts to change. Lack of motivation, fear of failure, unhealthy eating habits and a lack of exercise were cited as the most common obstacles. Alarmingly, 44% regain lost weight within six months, emphasising the need for more sustainable, long-term solutions that go beyond just lifestyle

adjustments.

As a conclusion, Vikrant Shrotriya, Corporate Vice President, Novo Nordisk India said, "Recent research has shed light on the perceptions and challenges faced by people living with obesity (PwO) in India. Despite the growing awareness, there are still significant misconceptions and hurdles that need to be addressed. Hence, involvement by the government is crucial in addressing

the growing obesity challenge in India. Obesity is not just an individual issue but a significant public health concern that impacts healthcare resources, economic productivity, and the overall well-being of our society. A multifaceted approach that includes policy interventions, awareness programs, and accessible healthcare solutions is essential to address this complex issue effectively."

## Biomarker test can detect Alzheimer's pathology earlier

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the University of Pittsburgh School of Medicine can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms that litter the brain, cerebrospinal fluid and potentially blood, new research published recently suggests.

The cerebrospinal fluid biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition, thereby opening doors for early-stage disease diagnosis and intervention.

Since amyloid-beta pathology often precedes tau abnormalities in Alzheimer's disease, most biomarker efforts have focused on early detection of amyloid-beta changes. However, the clumping of tau protein into well-ordered structures referred to by pathologists as "neurofibrillary tangles" is a more defining event for Alzheimer's disease as it is more strongly associated with the cog-

nitive changes seen in affected people.

"Our test identifies very early stages of tau tangle formation -- up to a decade before any tau clumps can show up on a brain scan," said senior author Thomas Karikari, Ph.D., assistant professor of psychiatry at Pitt. "Early detection is key to more successful therapies for Alzheimer's disease since trials show that patients with little-to-no quantifiable insoluble tau tangles are more likely to benefit from new treatments than those with a significant degree of tau brain deposits."

Since many elderly people who have amyloid-beta plaques in their brains will never go on to develop cognitive symptoms of Alzheimer's disease during their lifetime, the widely adopted diagnostics framework developed by the Alzheimer's Association specifies the three neuropathological pillars necessary to diagnose the disease -- combined presence of tau and amyloid-beta pathology and neurodegeneration.

## Clot-busting meds may be effective up to 24 hours

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary late-breaking science presented today at the American Stroke Association's International Stroke Conference 2025. The conference, in Los Angeles, Feb. 5-7, 2025, is a world premier meet-

ing for researchers and clinicians dedicated to the science of stroke and brain health.

These results give hope to stroke patients worldwide who may not be able to access clot-dissolving medications within the approved time window, which in China is within 4.5 hours, said the trial's principal investigator Min Lou, MD, PhD, a professor at the Second Affiliated Hospital of Zhejiang

University's School of Medicine in China.

In the U.S., alteplase is approved to treat stroke within three hours of symptom onset and is recommended for use up to 4.5 hours for select patients. Other research has indicated it may also work well in some patients 4.5 to 9 hours after stroke onset.

The American Heart Association/American Stroke Association 2019 Guidelines for the Early Management of Patients with Acute Ischemic Stroke note that IV alteplase within 4.5 hours of stroke onset is the standard of care for most ischemic stroke patients in the United States.

Researchers enrolled 372 stroke patients whose symptoms began 4.5 hours to 24 hours earlier. They used widely available CT perfusion imaging (advanced brain scanning) to confirm that these patients still had brain tissue that could recover with treatment. Participants were random-

ly split into two groups - one group received the clot-busting medication alteplase, while the other received standard stroke care of antiplatelet therapy at the discretion of the investigator, based on the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018. Functional recovery was assessed at 90 days.

"We believe these findings mean more people may return to normal or near-normal lives after a stroke, even if they receive treatment later than originally thought beneficial," Lou said. "This method of treatment could become the new standard, especially in hospitals that use CT perfusion imaging. This technology helps health care professionals see how blood flows in different parts of the brain after an ischemic stroke. This could extend treatment eligibility to millions more patients across the globe."

**VASTU HOUSING FINANCE CORPORATION LTD**  
Unit 203 & 204, 2nd Floor, "A" Wing, Navbharat Estate, Zakaria Bunder Road, Sewri (West), Mumbai 400015, Maharashtra.  
CIN No.: U65922MH2005PLC272501

**POSSESSION NOTICE**

Whereas, The undersigned being the Authorised Officer of Vastu Housing Finance Corporation Limited under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 and in exercise of powers conferred to him under section 13 (12) read with Rule 9 of the Security Interest (Enforcement) Rules 2002, issued a Demand Notice calling upon the borrowers mentioned herein below to repay the amount mentioned in respective notice within 60 days from the date of receipt of the said notice. The borrowers having failed to repay the amount, undersigned has taken possession of the property described herein below in exercise of powers conferred on me under Section 13(4) of the said Act read with Rule 9 of the said rules on the date mentioned below. The borrower and guarantor in particular and the public in general is hereby cautioned not to deal with the property and any dealings with the property will be subject to the charge of the Vastu Housing Finance Corporation Limited Branch for an amount mentioned as below and interest thereon, costs etc.

| S/N | Name of Borrower, Co-Borrower and LAN No.  | Date & Amount of Demand Notice           | Description of Property   | Date & Type of Possession              |
|-----|--|--|---|--|
| 1   | Kannan P (Applicant), Poongodi Kannan (Co-Applicant), Prabakaran T (Guarantor), HL000000099252 | 11-Nov-24<br>Rs. 1362925 as on 07-Nov-24 | SF No 542/4 Sub Div SF No 542/4A/542/4A1 Patta No 905 Ward No 11, Nallappanackkan Street, Chinnagoundanur Village Sankaragi Town Panchayat, Sankari, Salem, Tamil Nadu - 637301. Admeasuring 1870 Sq.ft. North-Gunasundari Buying Property, South-East West Pathway, East-Periyanna Gounder Vagayara Property, West-North South Pathway | Symbolic Possession Taken on 07-Feb-25 |

Date: 13.02.2025  
Place: Salem

Authorised officer  
Vastu Housing Finance Corporation Ltd

**homefirst**  
We'll take you home

**Home First Finance Company India Limited**  
CIN: L65990MH2010PLC240703  
Website: homefirstindia.com  
Phone No.: 180030008425 Email ID: loanfirst@homefirstindia.com

**POSSESSION NOTICE**

**REF: POSSESSION NOTICE UNDER SUB-RULE (1) OF RULE 8 OF THE SECURITY INTEREST (ENFORCEMENT) RULES, 2002**

WHEREAS the undersigned being the Authorized Officer of HOME FIRST FINANCE COMPANY INDIA LIMITED, pursuant to demand notice issued on its respective dates as given below, under the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 (Act No. 54 of 2002) and in exercise of powers conferred under section 13(2) read with rule 3 of the Security Interest (Enforcement) Rules, 2002, calling upon you/Borrowers, the under named to pay outstanding dues as within 60 days from the date of receipt of respective notices. You/Borrowers all, however, have failed to pay the said outstanding dues within stipulated time, hence HOME FIRST FINANCE COMPANY INDIA LIMITED are in exercise and having right as conferred under the provision of sub section (4) of section 13 of SARFAESI ACT, 2002 read with rules thereunder, taken POSSESSION of the secured assets as mentioned herein below:

| Sr. No | Name of Borrowers/ Co-Borrowers/ Guarantors          | Description of Mortgaged Property  | Date of Demand Notice | Total O/s as on date of Demand Notice (in INR) | Date of possession |
|--------|--|--|-----------------------|--|--------------------|
| 1.     | Rathinavel R, Shanthi R                              | House-Old SF.No: 778, New SF.No: 94, Site No:48 "Sree Devi Nagar", Panayampalli Village & Panchayat, Punjai Pullyampatti SRO, Sathiyamangalam Taluk, Erode District - 638459, Erode-638459. Bounded By: North by - Site No. 43, South by - 23' Wide East West Layout Road, East by - Site No. 49, West by - Site No. 47.   | 03-12-2024            | 18,60,935                                      | 08-02-2025         |
| 2.     | AJITH GOVINDHAN, GOVINDAN, GOVINDHAMMAL              | House-Site No. 201 South Part, S.F. No. 325/8A6, Arun Avenue Phase II, Arasampalayam, Kondampatti Village, Kinathukadavu Taluk, Coimbatore-642109. Bounded By: North by - Site No. 202 & 203, South by - Site No. 201 North part, East by: 10.0 Mtr Wide panchayat tar Road, West by - Site No. 196.   | 03-12-2024            | 16,84,634                                      | 08-02-2025         |
| 3.     | Masaniyammal K, Kamaraj .                            | House-Site No.70, Old S.F.No:778, New S.F.No:94, "Sri Devi Nagar", Panayampalli Village & Panchayat, Punjai Pullyampatti SRO, Sathiyamangalam Taluk, Erode District, Erode-638459. Bounded By: North by - Site No. 57, South by - 23' Wide East West Layout Road, East by - Site No. 71, West by - Site No. 69.  | 03-12-2024            | 11,79,166                                      | 08-02-2025         |
| 4.     | MANI KANDAN B, LAVANYA K                             | Flat-SF.No: 41/5B, Subdivision SF.No: 41/5B2C, Patta No: 247, Site No: 19 north west part, "Aishwarya Garden Phase - II", Kothavadi Village & Panchayat, Kinathukadavu SRO, Kinathukadavu Taluk, Coimbatore District - 642109, Coimbatore-642109. Bounded By: North by - Site No. 20, South by - 7.20 feet wide East West Layout Road, East by - Site No. 18, West by - Site No. 19 (North East) Part. | 03-12-2024            | 13,68,111                                      | 08-02-2025         |
| 5.     | Parameshwari V, Vetrivel D                           | Flat-SF.No:10/2A, Site No:1 (South Side One Part), Karuvallur Village & Panchayat, Avinashi Taluk & SRO, Tiruppur District - 641670, Tiruppur-641670. Bounded By: North by - Rangasamy Property, South by - Site No:1, Murali Property, East by - South North Road, West by - Ramasamy Property.   | 03-12-2024            | 13,96,248                                      | 08-02-2025         |
| 6.     | SURESHKUMAR MOHAN, Dhavamani Mohan, Mohan Yakambaram | House-RSF.No.481/1A6, Patta.No.3383, Site.No.861, Nelali village, Sri sairam Nagar-II, Kangeyam SRO, kangeyam Taluk, Tiruppur-638660. Bounded By: North by - Site No.846, South by - 23ft wide East west layout road, East by - Site No.862, West by - Site no.860   | 03-12-2024            | 10,91,675                                      | 08-02-2025         |

The borrower having failed to repay the amount, notice is hereby given to the borrower/ Guarantor and the public in general that the undersigned has taken Possession of the property described herein below in exercise of powers conferred on him/her under section 13(4) of the said Act read with rule 8 of the said rule on the date mentioned above.

The BORROWERS/ GUARANTORS and the PUBLIC IN GENERAL are hereby cautioned not to deal with the above referred Properties/Secured Assets or any part thereof and any dealing with the said Properties/Secured Assets shall be subject to charge of HOME FIRST FINANCE COMPANY INDIA LIMITED for the amount mentioned hereinabove against Properties/Secured Assets which is payable with the further interest thereon until payment in full.

The borrower's attention is invited to the provisions of subsection (8) of Section 13 of the Act, in respect of time available to redeem the secured asset.

Place: Coimbatore  
Date: 13-02-2025

Authorised Officer,  
Home First Finance Company India Limited

**ANIRIT VENTURES LIMITED**  
(Formerly Known as Flora Textiles Limited)  
CIN: L72100TJ1993PLC004290  
Registered Office: 23, Bharathi Park Road, Coimbatore - 641043, Tamil Nadu, India  
Website: www.floratextiles.in Email: aniritventures@gmail.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024**

The Board of Directors of the company at their meeting held on Tuesday, 11<sup>th</sup> February 2025, approved the unaudited financial results of the company for the quarter and nine months ended December 31, 2024.

The results are available on the stock exchange's website i.e. [www.bseindia.com](http://www.bseindia.com) and on the company website (URL: <https://aniritventures.com/investor-relations.html>). The same can be accessed by scanning the Quick Response (QR) code provided below:

By order of the Board  
For Anirit Ventures Limited  
Formerly Flora Textiles Limited  
Sd/-  
**Ms. Neha Thakkar (DIN: 10810103)**  
Wholetime Director & CFO

Place: Mumbai  
Date: February 11, 2025

